Takeda could acquire next-generation immunotherapies ... The company has had success with Ninlaro in multiple myeloma and its antibody-drug conjugate Adcetris in blood cancers including classical ...

Another candidate for AL amyloidosis – Takeda's Ninlaro (ixazomib) – flunked the phase 3 TOURMALINE-AL1 trial in 2019, but was subsequently shown to have had "clinically meaningful" effects on ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

3382.T Seven & i Holdings Co., Ltd.

Visit a quote page and your recently viewed tickers will be displayed here.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...